Home > Oncology > ASCO 2020 > Lung Cancer > ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

The addition of tremelimumab to frontline durvalumab and platinum-based chemotherapy did not demonstrate a statistically significant improvement in overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC), missing the co-primary endpoint of the phase 3 CASPIAN study.

Presented by Prof. Luis Paz-Ares (Hospital 12 de Octubre, Madrid, Spain), this was the first report of the third study arm of CASPIAN, in which investigational CTLA-4 inhibitor tremelimumab was added to PD-L1 checkpoint inhibitor durvalumab on top of standard of care chemotherapy [1].

CASPIAN randomised 805 patients to 3 treatment arms: durvalumab + tremelimumab + etoposide cisplatin/carboplatin (EP) (n=268), EP alone (n=269), or durvalumab + EP (n=268). The primary endpoint of the study was OS; secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safe...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on